Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis | Zendy

Eric L. Simpson | Zendy; Amy S. Paller | Zendy; Elaine C. Siegfried | Zendy; Mark Boguniewicz | Zendy; Lawrence Sher | Zendy; Melinda Gooderham | Zendy; Lisa A. Beck | Zendy; Emma GuttmanYassky | Zendy; David M. Pariser | Zendy; Andrew Blauvelt | Zendy; Jamie Weisman | Zendy; Benjamin Lockshin | Zendy; Thomas Hultsch | Zendy; Qin Zhang | Zendy; Mohamed Kamal | Zendy; John D. Davis | Zendy; Bolanle Akinlade | Zendy; Heribert Staudinger | Zendy; Jennifer D. Hamilton | Zendy; Neil M.H. Graham | Zendy; Gianluca Pirozzi | Zendy; Abhijit Gadkari | Zendy; Laurent Eckert | Zendy; Neil Stahl | Zendy; George D. Yancopoulos | Zendy; Marcella Ruddy | Zendy; Ashish Bansal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

Author(s) -

Eric L. Simpson,

Amy S. Paller,

Elaine C. Siegfried,

Mark Boguniewicz,

Lawrence Sher,

Melinda Gooderham,

Lisa A. Beck,

Emma GuttmanYassky,

David M. Pariser,

Andrew Blauvelt,

Jamie Weisman,

Benjamin Lockshin,

Thomas Hultsch,

Qin Zhang,

Mohamed Kamal,

John D. Davis,

Bolanle Akinlade,

Heribert Staudinger,

Jennifer D. Hamilton,

Neil M.H. Graham,

Gianluca Pirozzi,

Abhijit Gadkari,

Laurent Eckert,

Neil Stahl,

George D. Yancopoulos,

Marcella Ruddy,

Ashish Bansal

Publication year - 2019

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2019.3336

Subject(s) - medicine , dupilumab , eczema area and severity index , atopic dermatitis , randomized controlled trial , dermatology life quality index , scorad , placebo , population , quality of life (healthcare) , clinical endpoint , pediatrics , dermatology , disease , pathology , alternative medicine , nursing , environmental health

Adolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknown in this patient population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research